VP is a second-generation photosensitizer initially approved for the treatment of age-related macular degeneration, that acts as an inhibitor of the interaction of YAP with its transcriptional partner TEAD, causing the block of the transcriptional activation of YAP downstream targets55. This evidence concerns the gene YAP1 and age-related macular degeneration.